SCHEMBL20157144

SCHEMBL20157144

COCCOc1ncc2[nH]c(=O)n(Cc3cccc(C#N)c3)c2n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 2/20 0.49
NUDT1 P36639 2/20 0.49
GRIN1 Q05586 3/20 0.49
GRIN2B Q13224 3/20 0.49
CYP3A4 P08684 6/20 0.48
CYP2C9 P11712 6/20 0.48
ALDH1A1 P00352 6/20 0.48
CYP1A2 P05177 5/20 0.48
CYP2C19 P33261 4/20 0.48
HSD17B10 Q99714 3/20 0.48
CASP1 P29466 2/20 0.48
USP1 O94782 2/20 0.48
USP2 O75604 4/20 0.47
MAPK1 P28482 2/20 0.47
CLK4 Q9HAZ1 1/20 0.47
HIF1A Q16665 2/20 0.45
LMNA P02545 1/20 0.45
TSHR P16473 1/20 0.45
JAK2 O60674 3/20 0.45
JAK3 P52333 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20157446 0.89 USP1 (0.57) TLR7NUDT1GRIN1GRIN2BALDH1A1
SCHEMBL20157643 0.88 GRIN1 (0.46) TLR7GRIN1GRIN2BCYP3A4CYP2C9
SCHEMBL20157621 0.84 USP1 (0.45) TLR7NUDT1USP1JAK2JAK3
SCHEMBL21364059 0.84 JAK2 (0.49) TLR7NUDT1CYP3A4CYP2C9ALDH1A1
SCHEMBL20157629 0.83 TLR7 (0.50) TLR7NUDT1CYP3A4CYP1A2CYP2C19
SCHEMBL20157589 0.83 TLR7 (0.51) TLR7NUDT1CYP3A4CYP1A2CYP2C19
SCHEMBL20157432 0.83 TLR7 (0.51) TLR7NUDT1CYP3A4CYP1A2CYP2C19
SCHEMBL20157145 0.83 TLR7 (0.53) TLR7NUDT1USP1ADORA3
SCHEMBL20157595 0.82 TLR7 (0.50) TLR7NUDT1CYP3A4CYP1A2CYP2C19
SCHEMBL20157592 0.82 TLR7 (0.50) TLR7NUDT1CYP3A4CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11084818-B2 Nitrogen-containing heterocyclic compound, preparation method, intermediate, pharmaceutical composition and use HEPO PHARMACEUTICAL CO., LTD. (CN) 2021-08-10 US disclosed
US-20200062758-A1 Nitrogen-Containing Heterocyclic Compound, Preparation Method, Intermediate, Pharmaceutical Composition and use HEPO PHARMACEUTICAL CO., LTD. (CN) 2020-02-27 US disclosed
EP-3539963-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE Livo (Shanghai) Pharmaceutical Co., Ltd (CN) 2019-09-18 EP disclosed
WO-2018086593-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE 礼沃(上海)医药科技有限公司 2018-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11084818-B2 Nitrogen-containing heterocyclic compound, preparation method, intermediate, pharmaceutical composition and use TLR7, TLR9, TLR4 TLR7 1/4885NUDT1 15/4885GRIN1 2087/4885
US-20200062758-A1 Nitrogen-Containing Heterocyclic Compound, Preparation Method, Intermediate, Pharmaceutical Composition and use TLR7, TLR9, NOD1 TLR7 1/4885NUDT1 19/4885GRIN1 1034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.